The tumor microenvironment (TME) represents a highly complex system that encompasses cellular components (such as cancer cells, stromal cells, and immune cells) and non-cellular components (such as ...

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel ...

A new study published in Cancer Cell reveals that blocking a key nutrient-scavenging process in pancreatic tumors reprograms the tumor microenvironment—reducing fibrosis, enhancing T cell infiltration ...

Researchers at Oregon Health & Science University’s Knight Cancer Institute have developed a machine-learning tool that uses ...

The tumor microenvironment (TME) is a critical factor in antitumor immunity and treatment outcome in cancer therapy. We have ...

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become ...

Blocking a key metabolic enzyme helps B cells fight liver tumors, revealing a new immunotherapy pathway for fatty liver–driven cancer in mice.

This comprehensive review highlights the compositional and functional heterogeneity of intratumoral microbiota within the ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Several studies have now demonstrated that trained immunity occurs in the airways to several pathogens and products, while its utility is yet to be determined.

Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and ...

Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB ...